If these therapeutic approaches are stable, address HCC/HCA formation and translate into successful clinical trials, they offer an additional variant-specific therapeutic option that may result in permanent restoration of endogenous G6Pase-α expression. Here, G6PC1 is linked to hepatocellular carcinoma.